Sugi Predict

Sugi Predict / Compounds / SCHEMBL1014063

SCHEMBL1014063

SCHEMBL1014063

C[C@H](CCC(=O)OCI)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.81
▸ MEN1 O00255 2/20 0.81
▸ KMT2A Q03164 2/20 0.81
▸ USP2 O75604 2/20 0.81
▸ MAPK1 P28482 2/20 0.81
▸ LMNA P02545 1/20 0.81
▸ GPBAR1 Q8TDU6 10/20 0.76
▸ SLC10A2 Q12908 2/20 0.76
▸ TBXA2R P21731 1/20 0.76
▸ PDE3A Q14432 1/20 0.76
▸ NR1H4 Q96RI1 1/20 0.76
▸ CA1 P00915 3/20 0.69
▸ CA2 P00918 3/20 0.69
▸ ABCC4 O15439 1/20 0.64
▸ CYP2C9 P11712 1/20 0.64
▸ HIF1A Q16665 1/20 0.64
▸ VDR P11473 1/20 0.64
▸ CYP3A4 P08684 2/20 0.61
▸ SLCO1B3 Q9NPD5 1/20 0.61
▸ SLCO1B1 Q9Y6L6 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12362226 1.00 MAPT (0.81) MAPTMEN1KMT2AUSP2MAPK1
SCHEMBL22699678 0.92 MAPT (0.83) MAPTMEN1KMT2AUSP2MAPK1
SCHEMBL4971166 0.92 MAPT (0.83) MAPTMEN1KMT2AUSP2MAPK1
SCHEMBL18216458 0.91 MAPT (0.81) MAPTMEN1KMT2AUSP2MAPK1
SCHEMBL2260486 0.91 MAPT (0.81) MAPTMEN1KMT2AUSP2MAPK1
SCHEMBL23710355 0.91 MAPT (0.81) MAPTMEN1KMT2AUSP2MAPK1
SCHEMBL5431048 0.91 MAPT (0.81) MAPTMEN1KMT2AUSP2MAPK1
SCHEMBL17090568 0.91 MAPT (0.69) MAPTMEN1KMT2AUSP2MAPK1
SCHEMBL5436906 0.90 MAPT (0.80) MAPTMEN1KMT2AUSP2MAPK1
SCHEMBL5531597 0.90 MAPT (0.80) MAPTMEN1KMT2AUSP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200087338-A1 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK PHARMACEUTICALS INC (US) 2020-03-19 — — US disclosed
EP-3553072-A1 COMPOSITIONS COMPRISING DINUCLEOTIDE PRODRUGS Spring Bank Pharmaceuticals, Inc. (US) 2019-10-16 — — EP disclosed
US-10376533-B2 Compositions and methods for treating viral infections SPRING BANK PHARMACEUTICALS, INC. (US) 2019-08-13 — — US disclosed
US-10344046-B2 Nucleotide and oligonucleotide prodrugs SPRING BANK PHARMACEUTICALS, INC. (US) 2019-07-09 — — US disclosed
EP-3090748-B1 COMPOSITIONS COMPRISING NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK PHARMACEUTICALS INC (US) 2019-02-20 — — EP disclosed
US-20180273574-A1 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK PHARMACEUTICALS, INC. 2018-09-27 — — US disclosed
CN-107753499-A For treating the Compounds and methods for of virus infection 春堤制药公司 2018-03-06 — — CN disclosed
CN-103816174-B For treating the Compounds and methods for of virus infection 春堤制药公司 2017-12-05 — — CN disclosed
US-20170304344-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SPRING BANK PHARMACEUTICALS, INC. 2017-10-26 — — US disclosed
US-9539276-B2 Compositions and methods for treating viral infections SPRING BANK PHARMACEUTICALS, INC. (US) 2017-01-10 — — US disclosed
CN-101437397-B Nucleotide and oligonucleotide prodrugs SPRING BANK 2012-09-05 — — CN disclosed
US-8076303-B2 Nucleotide and oligonucleotide prodrugs SPRING BANK PHARMACEUTICALS, INC. (US) 2011-12-13 — — US disclosed
US-20110207690-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SPRING BANK PHARMACEUTICALS, INC. (US) 2011-08-25 — — US disclosed
CN-102123716-A Compounds and methods for treating viral infections SPRING BANK 2011-07-13 — — CN disclosed
EP-2271351-A2 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SPRING BANK (US) 2011-01-12 — — EP disclosed
WO-2009146123-A2 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SPRING BANK (US) 2009-12-03 — — WO disclosed
EP-1968612-A2 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK (US) 2008-09-17 — — EP disclosed
WO-2007070598-A9 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK (US) 2007-11-08 — — WO disclosed
US-20070149462-A1 Nucleotide and oligonucleotide prodrugs SPRING BANK PHARMACEUTICALS, INC. 2007-06-28 — — US disclosed
WO-2007070598-A2 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK (US) 2007-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087338-A1 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS TYMP, PNP, DUT MAPT 4011/4885MEN1 3192/4885KMT2A 2964/4885
US-10376533-B2 Compositions and methods for treating viral infections SLC10A1, HAVCR2, CYP3A43 MAPT 42/4885MEN1 2479/4885KMT2A 2552/4885
US-20110207690-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SLC10A1, HAVCR2, CYP3A43 MAPT 42/4885MEN1 2479/4885KMT2A 2552/4885
US-20070149462-A1 Nucleotide and oligonucleotide prodrugs TYMP, PNP, DUT MAPT 4011/4885MEN1 3192/4885KMT2A 2964/4885
US-10344046-B2 Nucleotide and oligonucleotide prodrugs TYMP, PNP, DUT MAPT 4011/4885MEN1 3192/4885KMT2A 2964/4885
US-20180273574-A1 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS TYMP, PNP, DUT MAPT 4011/4885MEN1 3192/4885KMT2A 2964/4885
US-20170304344-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SLC10A1, HAVCR2, CYP3A43 MAPT 42/4885MEN1 2479/4885KMT2A 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback